Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine botulinum neurotoxin D immune fab2
- Development stage
- Unknown
- Lead developer
- Cangene
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Equine Botulinum Neurotoxin D Immune FAB2 is a biologic antitoxin preparation composed of polyclonal antibody fragments (F(ab')₂) derived from equine plasma. It is used for the treatment of documented or suspected exposure to botulinum toxin serotype D. The mechanism of action involves passive immunization, where the F(ab')₂ antibody fragments bind and neutralize circulating (unbound) botulinum neurotoxin D, preventing it from interacting with nerve endings and being internalized into target cells. This helps prevent further progression of paralysis but does not reverse established paralysis once the toxin has bound to nerve terminals[1][5][7]. The product is typically manufactured by immunizing horses with inactivated forms of the toxin, collecting plasma, and purifying the relevant antibodies. Developers: Cangene Corporation Manufacturers: Emergent BioSolutions
- Other names
- equine botulinum neurotoxin d immune fab2
02
Targets
BoNT/D (Botulinum neurotoxin type D)
Beyond the preview
Go deeper on equine botulinum neurotoxin D immune fab2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine botulinum neurotoxin D immune fab2.